Why Agenus (AGEN) Stock Is Spiking Today

NEW YORK (TheStreet) -- Agenus (AGEN) shares are up 16.7% to $3.75 on Tuesday after the company announced that its experimental cancer vaccine helped patients with brain tumors live twice as long as those that received treatment without the vaccine.

Fifty percent of newly diagnosed glioblastoma multiforme (GBM) patients treated with the vaccine had their median overall survival time increased to two years in a mid-stage study.

Most GBM patients succumb to the disease within one year.

Must ReadWarren Buffett's 25 Favorite Stocks


AGEN Chart

AGEN data by YCharts

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

More from Markets

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Oil Slumps, Gas Spikes Ahead of Holiday Weekend; Assessing the Chipmakers--ICYMI

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Week Ahead: Wall Street Looks to Jobs Report as North Korea Meeting Less Certain

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Dow and S&P 500 Decline, Energy Shares Fall as U.S. Crude Oil Slides 4%

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Replay: Jim Cramer on the Markets, 10-Year Yield, Oil Prices and Foot Locker

Video: You Could Live in a Ritz-Carlton or St. Regis Home

Video: You Could Live in a Ritz-Carlton or St. Regis Home